REN and glioblastoma: Treatment of atypical anti-GBM disease has been heterogenous, including nonimmunosuppressive conservative therapies like renin-angiotensin-aldosterone blockers monotherapy (43.3%), immunosuppressive therapy like steroids, cyclophosphamide, mycophenolate mofetil, tacrolimus, rituximab (50%–70%), and rarely plasmapheresis (6.7%–10%).7